SUSPENSION OF SHARES FOR TRADING ON THE OFFICIAL LIST, ENTRY INTO VOLUNTARY ADMINISTRATION 

Ardana plc (LSE: ARA) ('Ardana' or the 'Company') 

Edinburgh, 30 June 2008: Ardana PLC announces that, at its own request, trading in the Company's ordinary shares was suspended with effect from 16.25 on Friday 27 June 2008, following which the Board has agreed to appoint Mr David Duggins and Mr Tom Burton of Ernst & Young LLP to act as Administrators of the Company from today.

The Board of Ardana has taken these steps after it became apparent that a possible refinancing or a possible sale or merger under discussion could not be completed within a timeframe during which the Board believed the Company would have sufficient cash reserves to continue trading. All discussions were terminated by the afternoon of Friday 27 June.

The Company has over recent months been in a number of licensing discussions for individual development products, however the Board have also concluded that these potential transactions could not be completed within the time available before exhaustion of the Company's cash resources. 

As a result, the Board of Ardana has taken advice and with great regret no longer believes that the Company is in a position to continue its operations.  It is expected that the appointment of administrators will formally occur later today, following which the Administrator will take such measures as they believe appropriate including continuing to seek a buyer for the Company and its assets. 

For further information please call: 

Mr David Duggins, Ernst & Young LLP

One Colmore Square, Birmingham, B4 6HQ, United Kingdom 

Telephone: +44 (0)121 535 2656 

Press Enquiries:

Michelle Wolf, Ernst & Young LLP

Telephone: +44 (0)207 980 0043

-------------------------------------------------------------------------------------------------------------------------------------------------------------

Ardana is an emerging pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, in order to address the areas of considerable unmet needs in this $25 billion-plus market.

Since Ardana’s foundation in July 2000 we have pursued a four-part strategy to create value from the business by:

• Maintaining a broad and balanced portfolio to manage risk, focusing on the therapeutic area of human reproductive health;

• Actively pursuing an in-licensing and acquisition programme for products and technologies to maintain a robust pipeline, including near-term commercial products and potential high value development candidates;

• Retaining value in our portfolio by building a sales and marketing capability in leading European markets, through both our own infrastructure and partnerships; and

• Maintaining a lean organisation by selective outsourcing in order to achieve flexibility.

Ardana operates a fully integrated pharmaceutical business model from research right through to sales and marketing.  Its experienced management team operates a virtual model in the areas of research, development (both pre clinical and clinical), manufacturing, regulatory and logistics using validated out-sourced suppliers to complete the work programmes designed internally.  Ardana has its own salesforce in the UK and marketing partners in Europe.

Currently Ardana’s key customers are endocrinologists and urologists and, as the portfolio expands, the customer profile will include other reproductive health specialists such as obstetricians and gynaecologists.  These are small, well-defined groups of clinicians easily addressed by a small team of sales representatives..

Ardana has rapidly established a broad and risk balanced product portfolio following  a series of research collaborations, licensing agreements, strategic product and company acquisitions.  This portfolio includes:

• Emselex ® a once a day treatment for the symptoms of overactive bladder syndrome which Ardana has exclusive UK marketing and promotion rights and is being distributed in collaboration with Novartis UK Limited

• Striant™ SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with confirmed hypogonadism;

• Invicorp ®, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe;

• Teverelix, a long acting formulation of a GnRH antagonist that provides dose-dependent control of the release of sex hormones such as testosterone in men and oestrogen in women.  Teverelix is in phase II development in two indications, prostate cancer and benign prostatic hyperplasia, and in phase I development in endometriosis.

• ARD-07 Oral GHS,  an oral growth hormone secretagogue currently in a pivotal registration study for the diagnosis of growth hormone deficiency in adults, and in early clinical development in a first therapeutic indication.

• Testosterone cream,  a transdermal testosterone delivery system in phase III development for the treatment of male hypogonadism and phase I development for a female indication.

In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana also has exclusive rights to commercialise research developed by the Medical Research Council (MRC) Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland. The HRSU is recognised by the World Health Organisation as one of the leading academic centres of excellence in reproductive biology in the world.  In addition it has research agreements with the Universities of Manchester and Montreal.

Ardana listed on the Main Board of the London Stock Exchange in March 2005. Stock ticker is ARA-L.  The company is led by a strong management team which has previous senior management experience within global pharmaceutical companies including Pharmacia, Wellcome, Merck, Aventis and Pfizer

.